464 related articles for article (PubMed ID: 27600563)
1. Diagnosis and treatment of Paget's disease of bone : A clinical practice guideline.
Muschitz C; Feichtinger X; Haschka J; Kocijan R
Wien Med Wochenschr; 2017 Feb; 167(1-2):18-24. PubMed ID: 27600563
[TBL] [Abstract][Full Text] [Related]
2. Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis.
Al Nofal AA; Altayar O; BenKhadra K; Qasim Agha OQ; Asi N; Nabhan M; Prokop LJ; Tebben P; Murad MH
Osteoporos Int; 2015 Jul; 26(7):1875-91. PubMed ID: 26037791
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.
Alvarez L; Guañabens N; Peris P; Vidal S; Ros I; Monegal A; Bedini JL; Deulofeu R; Pons F; Muñoz-Gomez J; Ballesta AM
Bone; 2001 Nov; 29(5):447-52. PubMed ID: 11704497
[TBL] [Abstract][Full Text] [Related]
4. Two cases of monostotic Paget's disease: effects of bisphosphonate.
Hoshiro M; Harada T; Iwai H; Miyatake T; Nishimura A; Ohno Y; Aoki N
Endocr J; 2003 Aug; 50(4):385-92. PubMed ID: 14599111
[TBL] [Abstract][Full Text] [Related]
5. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
6. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
[TBL] [Abstract][Full Text] [Related]
7. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
[TBL] [Abstract][Full Text] [Related]
8. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.
Alvarez L; Peris P; Pons F; Guañabens N; Herranz R; Monegal A; Bedini JL; Deulofeu R; Martínez de Osaba MJ; Muñoz-Gómez J; Ballesta AM
Arthritis Rheum; 1997 Mar; 40(3):461-8. PubMed ID: 9082934
[TBL] [Abstract][Full Text] [Related]
9. Paget's disease of bone: an endocrine society clinical practice guideline.
Singer FR; Bone HG; Hosking DJ; Lyles KW; Murad MH; Reid IR; Siris ES;
J Clin Endocrinol Metab; 2014 Dec; 99(12):4408-22. PubMed ID: 25406796
[TBL] [Abstract][Full Text] [Related]
10. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone.
Garnero P; Christgau S; Delmas PD
Bone; 2001 May; 28(5):461-4. PubMed ID: 11344044
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Bone Scintigraphy Results After Intravenous Zoledronate in Paget's Disease of Bone.
Reid IR; Maslowski K
Calcif Tissue Int; 2017 Jul; 101(1):43-49. PubMed ID: 28324123
[TBL] [Abstract][Full Text] [Related]
12. Paget's disease of bone: presentation, extent and response to bisphosphonates.
Wang LM; Au-Yeong ML; McKenna MJ
Ir Med J; 2002 Sep; 95(8):244, 246. PubMed ID: 12405502
[TBL] [Abstract][Full Text] [Related]
13. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson A
Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
[TBL] [Abstract][Full Text] [Related]
14. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
[TBL] [Abstract][Full Text] [Related]
15. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
de la Piedra C; Rapado A; Díaz Diego EM; Díaz Martín MA; Aguirre C; López Gavilanes E; Díaz Curiel M
Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976
[TBL] [Abstract][Full Text] [Related]
16. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
Reid IR; Miller P; Lyles K; Fraser W; Brown JP; Saidi Y; Mesenbrink P; Su G; Pak J; Zelenakas K; Luchi M; Richardson P; Hosking D
N Engl J Med; 2005 Sep; 353(9):898-908. PubMed ID: 16135834
[TBL] [Abstract][Full Text] [Related]
17. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
Hosking D; Lyles K; Brown JP; Fraser WD; Miller P; Curiel MD; Devogelaer JP; Hooper M; Su G; Zelenakas K; Pak J; Fashola T; Saidi Y; Eriksen EF; Reid IR
J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
[TBL] [Abstract][Full Text] [Related]
18. Biochemical response to bisphosphonate therapy in pagetic patients with skull involvement.
Peris P; Alvarez L; Vidal S; Kasper D; Leeming DJ; Monegal A; Angeles Martínez M; Pons F; Guañabens N
Calcif Tissue Int; 2006 Jul; 79(1):22-6. PubMed ID: 16868670
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of oral risedronate therapy in Japanese patients with Paget's disease of bone.
Ohara M; Imanishi Y; Nagata Y; Ishii A; Kobayashi I; Mori K; Ito M; Miki T; Nishizawa Y; Inaba M
J Bone Miner Metab; 2015 Sep; 33(5):584-90. PubMed ID: 25319558
[TBL] [Abstract][Full Text] [Related]
20. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone.
Arden-Cordone M; Siris ES; Lyles KW; Knieriem A; Newton RA; Schaffer V; Zelenakas K
Calcif Tissue Int; 1997 May; 60(5):415-8. PubMed ID: 9115157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
